A placebo-controlled trial of Korean red ginseng extract for preventing influenza-like illness in healthy adults

Ki-Chan Ha, Min-Gul Kim, Mi-Ra Oh, Eun-Kyung Choi, Hyang-Im Back, Sun-Young Kim, Eun-Ok Park, Dae-Young Kwon, Hye-Jeong Yang, Min-Jeong Kim, Hee-Joo Kang, Ju-Hyung Lee, Kyung-Min Choi, Soo-Wan Chae, Chang-Seop Lee, Ki-Chan Ha, Min-Gul Kim, Mi-Ra Oh, Eun-Kyung Choi, Hyang-Im Back, Sun-Young Kim, Eun-Ok Park, Dae-Young Kwon, Hye-Jeong Yang, Min-Jeong Kim, Hee-Joo Kang, Ju-Hyung Lee, Kyung-Min Choi, Soo-Wan Chae, Chang-Seop Lee

Abstract

Background: Standardized Korean red ginseng extract has become the best-selling influenza-like illness (ILI) remedy in Korea, yet much controversy regarding the efficacy of the Korean red ginseng (KRG) in reducing ILI incidence remains. The aim of the study is to assess the efficacy of the KRG extract on the ILI incidence in healthy adults.

Methods/design: We will conduct a randomized, double-blind, placebo-controlled study at the onset of the influenza seasons. A total of 100 subjects 30-70 years of age will be recruited from the general populations. The subjects will be instructed to take 9 capsules per day of either the KRG extract or a placebo for a period of 3 months. The primary outcome measure is to assess the frequency of ILI onset in participated subjects. Secondary variable measures will be included severity and duration of ILI symptoms. The ILI symptoms will be scored by subjects using a 4-point scale.

Discussion: This study is a randomized placebo controlled trial to evaluate the efficacy of the KRG extract compared to placebo and will be provided valuable new information about the clinical and physiological effects of the KRG extract on reduction of ILI incidence including flu and upper respiratory tract infections. The study has been pragmatically designed to ensure that the study findings can be implemented into clinical practice if KRG extract can be shown to be an effective reduction strategy in ILI incidence.

Trial registration: NCT01478009.

Figures

Figure 1
Figure 1
Flow diagram for study. Summary of the study flow.

References

    1. Kaye M, Skidmore S, Osman H, Weinbren M, Warren R. Surveillance of respiratory virus infections in adult hospital admissions using rapid methods. Epidemiol Infect. 2006;134(4):792–798. doi: 10.1017/S0950268805005364.
    1. Jansen AG, Sanders EA, Hoes AW, van Loon AM, Hak E. Influenza- and respiratory syncytial virus-associated mortality and hospitalisations. Eur Respir J. 2007;30(6):1158–1166. doi: 10.1183/09031936.00034407.
    1. Camps M, Ricart S, Dimova V, Rovira N, Munoz-Almagro C, Garcia JJ, Pons-Odena M, Marcos MA, Pumarola T. Prevalence of human metapneumovirus among hospitalized children younger than 1 year in Catalonia, Spain. J Med Virol. 2008;80(8):1452–1460. doi: 10.1002/jmv.21209.
    1. Johnson BF, Wilson LE, Ellis J, Elliot AJ, Barclay WS, Pebody RG, McMenamin J, Fleming DM, Zambon MC. Fatal cases of influenza a in childhood. PLoS One. 2009;4(10):e7671. doi: 10.1371/journal.pone.0007671.
    1. Singleton RJ, Bulkow LR, Miernyk K, DeByle C, Pruitt L, Hummel KB, Bruden D, Englund JA, Anderson LJ, Lucher L. et al.Viral respiratory infections in hospitalized and community control children in Alaska. J Med Virol. 2010;82(7):1282–1290. doi: 10.1002/jmv.21790.
    1. Hall CB. Hospital-acquired pneumonia in children: the role of respiratory viruses. Semin Respir Infect. 1987;2(1):48–56.
    1. Flamaing J, Engelmann I, Joosten E, Van Ranst M, Verhaegen J, Peetermans WE. Viral lower respiratory tract infection in the elderly: a prospective in-hospital study. Eur J Clin Microbiol Infect Dis. 2003;22(12):720–725. doi: 10.1007/s10096-003-1042-z.
    1. Cilla G, Onate E, Perez-Yarza EG, Montes M, Vicente D, Perez-Trallero E. Viruses in community-acquired pneumonia in children aged less than 3 years old: High rate of viral coinfection. J Med Virol. 2008;80(10):1843–1849. doi: 10.1002/jmv.21271.
    1. Aguilera JF, Paget WJ, Mosnier A, Heijnen ML, Uphoff H, van der Velden J, Vega T, Watson JM. Heterogeneous case definitions used for the surveillance of influenza in Europe. Eur J Epidemiol. 2003;18(8):751–754.
    1. Nichol KL. Heterogeneity of influenza case definitions and implications for interpreting and comparing study results. Vaccine. 2006;24(44-46):6726–6728. doi: 10.1016/j.vaccine.2006.05.064.
    1. Kirkpatrick GL. The common cold. Prim Care. 1996;23(4):657–675. doi: 10.1016/S0095-4543(05)70355-9.
    1. Engel JP. Viral upper respiratory infections. Semin Respir Infect. 1995;10(1):3–13.
    1. Lowenstein SR, Parrino TA. Management of the common cold. Adv Intern Med. 1987;32:207–233.
    1. Tyrrell DA, Cohen S, Schlarb JE. Signs and symptoms in common colds. Epidemiol Infect. 1993;111(1):143–156. doi: 10.1017/S0950268800056764.
    1. Gwaltney JM Jr. Rhinovirus infection of the normal human airway. Am J Respir Crit Care Med. 1995;152(4 Pt 2):S36–39.
    1. Tan BK, Vanitha J. Immunomodulatory and antimicrobial effects of some traditional chinese medicinal herbs: a review. Curr Med Chem. 2004;11(11):1423–1430.
    1. Scaglione F, Cattaneo G, Alessandria M, Cogo R. Efficacy and safety of the standardised Ginseng extract G115 for potentiating vaccination against the influenza syndrome and protection against the common cold [corrected] Drugs Exp Clin Res. 1996;22(2):65–72.
    1. Scaglione F, Ferrara F, Dugnani S, Falchi M, Santoro G, Fraschini F. Immunomodulatory effects of two extracts of Panax ginseng C.A. Meyer. Drugs Exp Clin Res. 1990;16(10):537–542.
    1. Lim DS, Bae KG, Jung IS, Kim CH, Yun YS, Song JY. Anti-septicaemic effect of polysaccharide from Panax ginseng by macrophage activation. J Infect. 2002;45(1):32–38. doi: 10.1053/jinf.2002.1007.
    1. Song JY, Han SK, Son EH, Pyo SN, Yun YS, Yi SY. Induction of secretory and tumoricidal activities in peritoneal macrophages by ginsan. Int Immunopharmacol. 2002;2(7):857–865. doi: 10.1016/S1567-5769(01)00211-9.
    1. Kim KH, Lee YS, Jung IS, Park SY, Chung HY, Lee IR, Yun YS. Acidic polysaccharide from Panax ginseng, ginsan, induces Th1 cell and macrophage cytokines and generates LAK cells in synergy with rIL-2. Planta Med. 1998;64(2):110–115. doi: 10.1055/s-2006-957385.
    1. Wang M, Guilbert LJ, Ling L, Li J, Wu Y, Xu S, Pang P, Shan JJ. Immunomodulating activity of CVT-E002, a proprietary extract from North American ginseng (Panax quinquefolium) J Pharm Pharmacol. 2001;53(11):1515–1523.
    1. Tomoda M, Hirabayashi K, Shimizu N, Gonda R, Ohara N, Takada K. Characterization of two novel polysaccharides having immunological activities from the root of Panax ginseng. Biol Pharm Bull. 1993;16(11):1087–1090. doi: 10.1248/bpb.16.1087.
    1. Shin KS, Kiyohara H, Matsumoto T, Yamada H. Rhamnogalacturonan II from the leaves of Panax ginseng C.A. Meyer as a macrophage Fc receptor expression-enhancing polysaccharide. Carbohydr Res. 1997;300(3):239–249. doi: 10.1016/S0008-6215(97)00055-4.
    1. Vohra S, Johnston BC, Laycock KL, Midodzi WK, Dhunnoo I, Harris E, Baydala L. Safety and tolerability of North American ginseng extract in the treatment of pediatric upper respiratory tract infection: a phase II randomized, controlled trial of 2 dosing schedules. Pediatrics. 2008;122(2):e402–410. doi: 10.1542/peds.2007-2186.
    1. McElhaney JE, Goel V, Toane B, Hooten J, Shan JJ. Efficacy of COLD-fX in the prevention of respiratory symptoms in community-dwelling adults: a randomized, double-blinded, placebo controlled trial. J Altern Complement Med. 2006;12(2):153–157. doi: 10.1089/acm.2006.12.153.
    1. Predy GN, Goel V, Lovlin R, Donner A, Stitt L, Basu TK. Efficacy of an extract of North American ginseng containing poly-furanosyl-pyranosyl-saccharides for preventing upper respiratory tract infections: a randomized controlled trial. CMAJ. 2005;173(9):1043–1048. doi: 10.1503/cmaj.1041470.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner